ARDENT HEALTH INC (ARDT) Stock Fundamental Analysis
USA - NYSE:ARDT - US03980N1072 - Common Stock
13.31 USD
+0.49 (+3.82%)
13.31 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to ARDT. ARDT was compared to 101 industry peers in the Health Care Providers & Services industry. ARDT has only an average score on both its financial health and profitability. ARDT scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
ARDT had positive earnings in the past year.
In the past year ARDT had a positive cash flow from operations.
1.2 Ratios
ARDT has a better Return On Assets (5.07%) than 78.22% of its industry peers.
ARDT has a better Return On Equity (20.31%) than 88.12% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.74%, ARDT is in the better half of the industry, outperforming 76.24% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ARDT is below the industry average of 9.19%.
The 3 year average ROIC (5.96%) for ARDT is below the current ROIC(8.74%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.07% | ||
| ROE | 20.31% | ||
| ROIC | 8.74% |
ROA(3y)3.2%
ROA(5y)N/A
ROE(3y)18.73%
ROE(5y)N/A
ROIC(3y)5.96%
ROIC(5y)N/A
1.3 Margins
ARDT's Profit Margin of 4.11% is fine compared to the rest of the industry. ARDT outperforms 73.27% of its industry peers.
In the last couple of years the Profit Margin of ARDT has grown nicely.
With a decent Operating Margin value of 6.97%, ARDT is doing good in the industry, outperforming 70.30% of the companies in the same industry.
In the last couple of years the Operating Margin of ARDT has grown nicely.
ARDT's Gross Margin of 57.76% is fine compared to the rest of the industry. ARDT outperforms 79.21% of its industry peers.
In the last couple of years the Gross Margin of ARDT has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.97% | ||
| PM (TTM) | 4.11% | ||
| GM | 57.76% |
OM growth 3Y3%
OM growth 5YN/A
PM growth 3Y3.64%
PM growth 5YN/A
GM growth 3Y2.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ARDT is still creating some value.
ARDT has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ARDT has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.18 indicates that ARDT is not a great score, but indicates only limited risk for bankruptcy at the moment.
ARDT has a Altman-Z score (2.18) which is comparable to the rest of the industry.
The Debt to FCF ratio of ARDT is 10.26, which is on the high side as it means it would take ARDT, 10.26 years of fcf income to pay off all of its debts.
ARDT has a Debt to FCF ratio (10.26) which is in line with its industry peers.
A Debt/Equity ratio of 0.87 indicates that ARDT is somewhat dependend on debt financing.
ARDT has a worse Debt to Equity ratio (0.87) than 60.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 10.26 | ||
| Altman-Z | 2.18 |
ROIC/WACC1.04
WACC8.4%
2.3 Liquidity
ARDT has a Current Ratio of 2.13. This indicates that ARDT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARDT (2.13) is better than 75.25% of its industry peers.
A Quick Ratio of 2.00 indicates that ARDT should not have too much problems paying its short term obligations.
The Quick ratio of ARDT (2.00) is better than 75.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
ARDT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 314.38%, which is quite impressive.
Measured over the past years, ARDT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.75% on average per year.
ARDT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.29%.
ARDT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.00% yearly.
EPS 1Y (TTM)314.38%
EPS 3Y13.75%
EPS 5YN/A
EPS Q2Q%52.94%
Revenue 1Y (TTM)10.29%
Revenue growth 3Y7%
Revenue growth 5YN/A
Sales Q2Q%11.85%
3.2 Future
The Earnings Per Share is expected to grow by 21.38% on average over the next years. This is a very strong growth
Based on estimates for the next years, ARDT will show a small growth in Revenue. The Revenue will grow by 6.53% on average per year.
EPS Next Y52.25%
EPS Next 2Y26.27%
EPS Next 3Y21.38%
EPS Next 5YN/A
Revenue Next Year8.61%
Revenue Next 2Y6.79%
Revenue Next 3Y6.53%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.44, the valuation of ARDT can be described as very cheap.
Based on the Price/Earnings ratio, ARDT is valued cheaper than 98.02% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.41, ARDT is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.79, the valuation of ARDT can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ARDT indicates a rather cheap valuation: ARDT is cheaper than 97.03% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ARDT to the average of the S&P500 Index (22.88), we can say ARDT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.44 | ||
| Fwd PE | 6.79 |
4.2 Price Multiples
96.04% of the companies in the same industry are more expensive than ARDT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ARDT is valued a bit cheaper than the industry average as 70.30% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.62 | ||
| EV/EBITDA | 4.13 |
4.3 Compensation for Growth
ARDT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ARDT may justify a higher PE ratio.
A more expensive valuation may be justified as ARDT's earnings are expected to grow with 21.38% in the coming years.
PEG (NY)0.14
PEG (5Y)N/A
EPS Next 2Y26.27%
EPS Next 3Y21.38%
5. Dividend
5.1 Amount
ARDT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.31
+0.49 (+3.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners73.34%
Inst Owner Change0.63%
Ins Owners1.98%
Ins Owner Change1.21%
Market Cap1.90B
Analysts81.18
Price Target19.84 (49.06%)
Short Float %1.98%
Short Ratio5.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.13%
Min EPS beat(2)43.05%
Max EPS beat(2)71.2%
EPS beat(4)3
Avg EPS beat(4)36.54%
Min EPS beat(4)-44.28%
Max EPS beat(4)76.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.16%
Min Revenue beat(2)-2.01%
Max Revenue beat(2)4.33%
Revenue beat(4)2
Avg Revenue beat(4)1.58%
Min Revenue beat(4)-2.11%
Max Revenue beat(4)6.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.91%
PT rev (3m)-3.53%
EPS NQ rev (1m)-0.65%
EPS NQ rev (3m)-5.06%
EPS NY rev (1m)-4.12%
EPS NY rev (3m)-3.9%
Revenue NQ rev (1m)-0.32%
Revenue NQ rev (3m)0.06%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.44 | ||
| Fwd PE | 6.79 | ||
| P/S | 0.31 | ||
| P/FCF | 17.62 | ||
| P/OCF | 6.31 | ||
| P/B | 1.52 | ||
| P/tB | 6.35 | ||
| EV/EBITDA | 4.13 |
EPS(TTM)1.79
EY13.45%
EPS(NY)1.96
Fwd EY14.73%
FCF(TTM)0.76
FCFY5.68%
OCF(TTM)2.11
OCFY15.85%
SpS43.31
BVpS8.77
TBVpS2.1
PEG (NY)0.14
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.07% | ||
| ROE | 20.31% | ||
| ROCE | 10.43% | ||
| ROIC | 8.74% | ||
| ROICexc | 10.05% | ||
| ROICexgc | 13.67% | ||
| OM | 6.97% | ||
| PM (TTM) | 4.11% | ||
| GM | 57.76% | ||
| FCFM | 1.74% |
ROA(3y)3.2%
ROA(5y)N/A
ROE(3y)18.73%
ROE(5y)N/A
ROIC(3y)5.96%
ROIC(5y)N/A
ROICexc(3y)6.85%
ROICexc(5y)N/A
ROICexgc(3y)9.47%
ROICexgc(5y)N/A
ROCE(3y)7.12%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y3%
OM growth 5YN/A
PM growth 3Y3.64%
PM growth 5YN/A
GM growth 3Y2.83%
GM growth 5YN/A
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 10.26 | ||
| Debt/EBITDA | 1.87 | ||
| Cap/Depr | 129.12% | ||
| Cap/Sales | 3.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 51.85% | ||
| Profit Quality | 42.43% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 2 | ||
| Altman-Z | 2.18 |
F-Score8
WACC8.4%
ROIC/WACC1.04
Cap/Depr(3y)111.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)314.38%
EPS 3Y13.75%
EPS 5YN/A
EPS Q2Q%52.94%
EPS Next Y52.25%
EPS Next 2Y26.27%
EPS Next 3Y21.38%
EPS Next 5YN/A
Revenue 1Y (TTM)10.29%
Revenue growth 3Y7%
Revenue growth 5YN/A
Sales Q2Q%11.85%
Revenue Next Year8.61%
Revenue Next 2Y6.79%
Revenue Next 3Y6.53%
Revenue Next 5YN/A
EBIT growth 1Y87.99%
EBIT growth 3Y10.2%
EBIT growth 5YN/A
EBIT Next Year69.06%
EBIT Next 3Y25.53%
EBIT Next 5YN/A
FCF growth 1Y51.28%
FCF growth 3Y152.66%
FCF growth 5YN/A
OCF growth 1Y42.1%
OCF growth 3Y28.95%
OCF growth 5YN/A